MicroPort

50 products. 11 consecutive years. MicroPort and its associated companies have now reached 50 products accepted into China’s NMPA Innovative Medical Device Special Review Program, commonly known as the Green Channel. For the 11th consecutive year, MicroPort ranks first among medical device companies in China by number of products entering the program. The 50th product is NuWismen®, a liquid embolic agent being developed by MicroPort NeuroScientific for the treatment of cerebrovascular malformations. From cardiac care and vascular intervention to robotics, neuroscience and orthopedics, these 50 technologies address very different clinical challenges. What connects them is how innovation takes shape at MicroPort: clinical needs, inventive engineering, and teams doing the work to turn new ideas into practical solutions. 50 is a milestone. The work continues. Learn more: https://lnkd.in/ezGKWEYF #MicroPort #MedicalInnovation #MedTech #HealthcareInnovation #BetterAndLongerLives

💙 At MicroPort, we believe the little details make all the difference. Understanding the complexity behind every condition. Delivering high-quality solutions that change lives. Building partnerships with medical communities around the world. This is what drives us every day, across every market we serve. 🔗 Learn more: https://microport.com #MicroPort #BetterAndLongerLives #MedTech #HealthcareInnovation

“A wide range of possibilities.” - Prof. Dr. Alexandre Abizaid Following his visit to MicroPort, Prof. Dr. Alexandre Abizaid, Director of Hemodynamics and Interventional Cardiology at the Heart Institute (InCor), University of São Paulo, Brazil, reflects on the breadth of MicroPort's coronary technologies - from lesion preparation for complex PCI to solutions supporting the evolving needs of the cath lab. #MicroPort #InterventionalCardiology #ComplexPCI #BetterAndLongerLives

How can DAPT duration be personalized after PCI? Prof. Gilles Montalescot shares his perspective on the TARGET-FIRST trial, recently recognized as a landmark study by the European Heart Journal, and how its findings support a more personalized approach to antiplatelet therapy for carefully selected AMI patients. 🎥 Watch the full interview : https://lnkd.in/eDSuPhi4 Follow #TARGETFIRSTPerspectives for expert voices from Europe, Asia, and the Americas on what TARGET-FIRST means for everyday clinical practice. #ShortDAPT #TargetFirst #PCI #InterventionalCardiology

New clinical milestones in Türkiye! 🇹🇷🚀 At Lokman Hekim Sağlık Grubu Hospital, Assoc. Prof. Dr. Gokhan Akkurt and his team successfully performed the first robotic Ivor Lewis esophagectomy using the Toumai® system. This procedure also marked the first thoracic docking with Toumai® in the country. Ivor Lewis esophagectomy is one of the most technically demanding procedures in upper GI surgery. Completing it robotically, across both abdominal and thoracic phases in a high-risk patient, is a testament to the expertise of the surgical team and the precision of the platform. Proud to see Toumai® reaching new frontiers, one complex procedure at a time, towards #BetterAndLongerLives. Congratulations to the entire team on this remarkable achievement! 🔗 Learn more about Toumai: https://lnkd.in/gPPzCY34 Behic Danisan | Ebru Güneş | ilker ahmet bulca #MicroPort #Toumai #SurgicalRobotics #MedTech

From global expansion to advances in satellite-enabled robotic telesurgery, regulatory progress and clinical research, H1 2026 marked a significant period of momentum for MicroPort®. Each milestone reflects our continued commitment to advancing medical technologies and expanding access to innovation worldwide. #MicroPort #MedTech #MedicalInnovation #HealthcareInnovation #BetterAndLongerLives